We have an passive "buy-alert" on AVII. several Asset Managements has their eyes on AVII, because the Stock will rise in the next 1-2 years. Im a critical biotech-Trader/Investor who sees a really good potential. The Phase 1b/2 trials were really good. The Drug AVI-4658 (Duchenne) showed a strong positive Results. It will be the first Drug for AVII who will get an FDA Approval. Thats what i see and thats a Reason for me to stay in long-term on AVII.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=AVII.O×tamp=20100602110100
(SmallCap and Barrons are bullish on AVII)
AVI BioPharma, Inc. Announces AVI-4658 Demonstrates First Ever Reported Generation Of Greater Than 50% Dystrophin-Positive Muscle Fibers In A Patient
AVI BioPharma, Inc. announced topline biopsy data from Study 28, the ongoing Phase 1b/2 clinical trial of AVI-4658, AVI's lead drug candidate being developed as a systemically administered treatment for a substantial subgroup of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. Topline biopsy data from the study demonstrated the first ever reported generation of new dystrophin-positive muscle fibers of more than 50% of normal in a patient with DMD following systemic administration of a drug. All patients in the two highest dose cohorts of the study demonstrated generation of new dystrophin-positive muscle fibers, although treatment responses varied across and within treatment groups. Generation of functional dystrophin is considered critical for successful treatment of DMD, and AVI intends further clinical evaluation of AVI-4658 to help optimize a dosing regimen to achieve more consistent improvements among patients. AVI-4658 was generally well tolerated in all Study 28 patients, and there has been no evidence of anti-dystrophin antibodies or T and B cell infiltration. In the patients completing dosing, two serious adverse events (one instance each of post operative nausea and vomiting, and an ankle fracture), both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period of the trial.
